By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

According to data from two phase III trials presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium, patients with high-risk prostate cancer had a significantly ...

Prostatectomy and radiation therapy show no survival difference for low-risk prostate cancer, but higher-risk cases require careful treatment consideration. The ProtecT trial supports active ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

Prostate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each year. For many patients, radiotherapy is a standard treatment option that ...

Researchers found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, is as safe as conventional treatment, with similar side effects and a ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Receiving radiotherapy after prostatectomy does negatively affect long-term health-related quality of life, including sexual function, urinary incontinence, and urinary irritation, but the timing of ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...

SpaceOAR Hydrogel reduces radiation exposure to the rectum, minimizing bowel-related side effects in prostate cancer patients undergoing radiation therapy. A study showed a 25% reduction in bowel ...